A pharmaceutical formulation, comprising at least one mGluR5 receptor negative Western Hemisphere modulator and at least one pharmaceutically acceptable precursor in the form of anesthetics, enteric sac or multi unit dose, improves the activity of treating Parkinson's disease. 1: Drug preparation including at least one negative Western chromatographic transformer mGluR5 and at least one intestinal coating,In this case, the components of the gut coating are selected and the drug formulation will release a negative Western pigment receptor Claim 7: according to one of the 1-6 requirements, i.e. as a negative herring modulator of mGluR5 receptor, the pharmaceutical preparation includes a pyrazole compound [1,5-a] pyridine (1) or an optical isomer, a pharmaceutically acceptable salt, hydrate, solvent or polymorphine, R1 represents chlorine or bromine； R2, R3, R4, R5, R6 and R7 may be the same or different, respectively representing hydrogen, C1-6 tar and ammonia water,Hydrogen Xi, halogen or sulfur trifluoride； R8 and R9, together with the carbon atoms connected to them, can form an unsaturated circular system, which contains 5 to 7 (i.e. 5, 6 or 7) carbon atoms, of which 0 to 4 (i.e. 0, 1, 2), The carbon atoms (Class 3 or 4) in a ring system consisting of R8 and R9 may be replaced by heteroatoms independently selected from nitrogen, oxygen and sulfur, in which case the ring system may be replaced by one or more substitutes (e.g. 1, 2 or 3), They may be the same or different, independently selected from halogen, amino, hydroxy, nitrogen, cyanogen,- 1-1-1-1-1-1, 1-1-1-1-1-1-1-1-1-1-1-1-1, 1-1-1-6 ILO And bike c3-12.Una formulación farmacéutica que comprende al menos un modulador alostérico negativo del receptor mGluR5 y al menos un excipiente farmacéuticamente aceptable en forma de un comprimido entérico, cápsula entérica o forma de dosificación unitaria múltiple mejoró la actividad para el tratamiento de la enfermedad de Parkinson.Reivindicación 1: Formulación farmacéut
